D
Daniel W. Hommes
Researcher at University of California, Los Angeles
Publications - 181
Citations - 9379
Daniel W. Hommes is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Inflammatory bowel disease & Crohn's disease. The author has an hindex of 47, co-authored 180 publications receiving 8253 citations. Previous affiliations of Daniel W. Hommes include Leiden University & University of California.
Papers
More filters
Journal ArticleDOI
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Henri Braat,Pieter Rottiers,Daniel W. Hommes,Nathalie Huyghebaert,Erik Remaut,Jean Paul Remon,Sander J. H. van Deventer,Sabine Neirynck,Sabine Neirynck,Maikel P. Peppelenbosch,Lothar Steidler,Lothar Steidler +11 more
TL;DR: Here it is shown that the use of genetically modified bacteria for mucosal delivery of proteins is a feasible strategy in human beings and is suitable as maintenance treatment for chronic intestinal disease.
Journal ArticleDOI
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel,Remo Panaccione,Peter Bossuyt,Milan Lukas,Filip Baert,Tomáš Vaňásek,Ahmet Danalioglu,Gottfried Novacek,Alessandro Armuzzi,Xavier Hébuterne,Simon Travis,Silvio Danese,Walter Reinisch,William J. Sandborn,Paul Rutgeerts,Daniel W. Hommes,Stefan Schreiber,Ezequiel Neimark,Bidan Huang,Qian Zhou,Paloma Mendez,J Petersson,Kori Wallace,Anne M. Robinson,Roopal Thakkar,Geert R. D'Haens +25 more
TL;DR: This trial aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients management with a clinical management algorithm.
Journal ArticleDOI
Development of the Crohn's disease digestive damage score, the Lémann score†‡§
Benjamin Pariente,Jacques Cosnes,Silvio Danese,William J. Sandborn,Maãté Lewin,Joel G. Fletcher,Yehuda Chowers,Geert R. D'Haens,Brian G. Feagan,Toshifumi Hibi,Daniel W. Hommes,E. Jan Irvine,Michael A. Kamm,Edward V. Loftus,Edouard Louis,Pierre Michetti,Pia Munkholm,Tom Øresland,Julián Panés,Laurent Peyrin-Biroulet,Walter Reinisch,Bruce E. Sands,Juergen Schoelmerich,Stefan Schreiber,Herbert Tilg,Simon Travis,Gert Van Assche,Maurizio Vecchi,Jean Yves Mary,Jean-Frederic Colombel,Marc Lémann +30 more
TL;DR: The methods to develop an instrument that can measure cumulative bowel damage, called the Crohn's Disease Digestive Damage Score (the Lémann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection are outlined.
Journal ArticleDOI
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
TL;DR: The crux of the matter should be the design of qualitatively new drugs, such as selective glucocorticoid receptor agonists (SEGRAs).
Journal ArticleDOI
Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis.
Marjolijn Duijvestein,Manon E. Wildenberg,Mick M. Welling,Simone D. Hennink,Ilse Molendijk,Vanessa L. van Zuylen,Tjalling Bosse,Anne Christine W. Vos,Eveline S.M. de Jonge-Muller,Helene Roelofs,Louise van der Weerd,Hein W. Verspaget,Willem E. Fibbe,Anje A. te Velde,Gijs R. van den Brink,Daniel W. Hommes +15 more
TL;DR: It is demonstrated that IFN‐γ activation of MSCs increases their immunosuppresive capacities and importantly, their therapeutic efficacy in vivo, and prestimulation of MMSs with IFN-γ enhances their capacity to inhibit Th1 inflammatory responses, resulting in diminished mucosal damage in experimental colitis.